X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Quality Issues Lead To Novartis Halting Cancer Radiotherapy

Content Team by Content Team
10th May 2022
in News

Novartis has halted production of its two commercial radioligand treatments for cancer care just weeks after the FDA approved them.

Novartis confirmed on May 5th that production of Lutathera, a neuroendocrine tumour medication, and Pluvicto, a newly approved prostate cancer drug, has indeed been temporarily suspended at its plants in Ivrea, Italy, and also Millburn, New Jersey.

The drastic move is being taken as an extra precaution as a consequence of potential quality concerns detected in its manufacturing steps, according to the business. A Novartis spokeswoman declined to share any additional information on the problem. Due to an unexpected manufacturing error, Novartis has suspended shipping of Lutathera and Pluvicto to consumers in the United States and Canada. Pluvicto obtained FDA approval for recently managed, PSMA-positive, metastatic castration-resistant prostate cancer just six weeks ago, so the supply stoppage is shocking.

Pluvicto clinical trials have ceased worldwide, as have Lutathera’s clinical trials in the United States and Canada. There is now no indication that patients who got dosages already administered at such sites are at danger, as per Novartis. Nonetheless, company is requesting that designated radioligand therapy treatment centres keep monitoring patients who have recently been injected and disclose any adverse reactions.

Novartis has notified regulators and is undertaking an investigation. It intends to overcome the concerns and continue some deliveries in the next six weeks, as per the company’s schedule. In a statement, Novartis added that they know that this circumstance impacts patients, their families, including care teams.Novartis takes this incredibly seriously, and the company will do everything it can to correct the problem and get patient dosages back to normal as soon as possible.

Meanwhile, one Novartis radioligand therapy manufacturing location in Zaragoza, Spain, continues to produce Lutathera for Europe and Asia, albeit Novartis cautions about possible supply delays.

Both Lutathera and Pluvicto are radioligand therapeutics, which CEO Vas Narasimhan has identified as one of the Swiss pharma’s main technologically advanced platforms, alongside RNA medicines, cell and gene treatments, and other sophisticated technologies. Radioligand treatments, according to Novartis, integrate therapeutic radioactive isotopes with cell-targeting chemicals called ligands. The radioisotopes are created in dedicated nuclear reactors before being combined with the ligand in a manufacturing facility. The completed product is packed in lead-free containers and delivered to treatment facilities.

Novartis has made mistakes in the production of breakthrough therapies before. The business struggled to maintain the final product within commercial criteria during the early introduction of CAR-T cell therapy Kymriah in blood malignancies. Early physician trust in Kymriah was harmed in favour of Gilead Sciences’ competitor CAR-T therapy, Yescarta, due to that initial setback.

Previous Post

FDA Regulates Use of J&J COVID Jab Due To Risk Of Thrombosis

Next Post

Sanofi Drug Components Venture Comes To Life After Two Years

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
Next Post
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Sanofi Drug Components Venture Comes To Life After Two Years

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In